Summit Therapeu ADR (SMMT)

$13.88 -0.25 (-1.77%)
Market Cap 10.87B
Revenue (ttm) 0.00
Net Income (ttm) -1.08B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,897,313
Avg Vol 5,156,922
Day's Range N/A - N/A
Shares Out 776.16M
Stochastic %K 49%
Beta -1.32
Analysts Sell
Price Target $29.31

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 203 2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
ItsMuffinMan
ItsMuffinMan Jun. 16 at 4:31 PM
$SMMT
0 · Reply
Bazziggr
Bazziggr Jun. 16 at 4:07 PM
$SMMT JUNK
0 · Reply
Dragonland
Dragonland Jun. 16 at 2:08 PM
$SMMT really expected more momentum from the buys last week. Market still very down on Summit for some strange reason.
1 · Reply
DakHart
DakHart Jun. 16 at 11:55 AM
$SMMT
0 · Reply
SmokeWagon
SmokeWagon Jun. 16 at 10:30 AM
$SMMT !!! The Tide has turned.
0 · Reply
paweltrader
paweltrader Jun. 16 at 3:36 AM
$SMMT Officer Zanganeh Mahkam bought 3.8M shares for $49.99M. Real-time insider alerts, no delay. watch4insider.com
0 · Reply
DakHart
DakHart Jun. 16 at 1:09 AM
$SMMT was really hopeful this morning for a push back to 15. I do think 15 is obtainable this week tho!
0 · Reply
Reneejordan001
Reneejordan001 Jun. 15 at 7:36 PM
$SMMT Just started enrollment for Triple negative breast cancer 👇👌
1 · Reply
DakHart
DakHart Jun. 15 at 7:26 PM
$SMMT might have to wait for some good trial data come August timeframe. I fear the dilution fears are too strong for the insider signals to matter for large growth.
1 · Reply
Boom1166
Boom1166 Jun. 15 at 5:43 PM
$SMMT
0 · Reply
Latest News on SMMT
Summit Therapeutics withdraws proposed underwritten public offering

2026-06-11T13:50:22.000Z - 5 days ago

Summit Therapeutics withdraws proposed underwritten public offering

Summit Therapeutics falls -10.2%

2026-06-10T16:07:19.000Z - 6 days ago

Summit Therapeutics falls -10.2%

Summit Therapeutics put volume heavy and directionally bearish

2026-06-10T15:35:09.000Z - 6 days ago

Summit Therapeutics put volume heavy and directionally bearish

Summit Therapeutics Transcript: AGM 2026

Jun 10, 2026, 8:30 AM EDT - 6 days ago

Summit Therapeutics Transcript: AGM 2026

Summit Therapeutics announces $500M common stock offering

2026-06-09T20:50:10.000Z - 6 days ago

Summit Therapeutics announces $500M common stock offering

Summit Therapeutics Announces Proposed Public Offering of Common Stock

Jun 9, 2026, 4:47 PM EDT - 6 days ago

Summit Therapeutics Announces Proposed Public Offering of Common Stock

Summit Therapeutics files automatic mixed securities shelf

2026-06-09T20:35:40.000Z - 6 days ago

Summit Therapeutics files automatic mixed securities shelf

Summit Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 11:00 AM EDT - 8 days ago

Summit Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

The Era of the One-Size-Fits-All Cancer Drug Is Ending

Jun 6, 2026, 5:30 AM EDT - 10 days ago

The Era of the One-Size-Fits-All Cancer Drug Is Ending

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

Jun 4, 2026, 4:30 PM EDT - 11 days ago

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

Jun 1, 2026, 8:06 AM EDT - 15 days ago

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

Summit Therapeutics Transcript: Status update

Jun 1, 2026, 7:00 AM EDT - 15 days ago

Summit Therapeutics Transcript: Status update

Summit Therapeutics Press release: Status update

Jun 1, 2026, 7:00 AM EDT - 15 days ago

Summit Therapeutics Press release: Status update

Summit Therapeutics Slides: Status update

Jun 1, 2026, 7:00 AM EDT - 15 days ago

Summit Therapeutics Slides: Status update

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Jun 1, 2026, 6:34 AM EDT - 15 days ago

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

ONC RVMD

Summit Therapeutics announces OS results from Phase 3 HARMONi-6 trial

2026-05-31T13:50:05.000Z - 16 days ago

Summit Therapeutics announces OS results from Phase 3 HARMONi-6 trial

Summit Therapeutics presents new results from AK112-206 trial

2026-05-31T13:35:51.000Z - 16 days ago

Summit Therapeutics presents new results from AK112-206 trial

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

May 31, 2026, 9:06 AM EDT - 16 days ago

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

May 31, 2026, 8:00 AM EDT - 16 days ago

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

May 30, 2026, 8:00 AM EDT - 17 days ago

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

Summit Therapeutics management to meet with Cantor

2026-05-26T21:01:32.000Z - 20 days ago

Summit Therapeutics management to meet with Cantor

Summit Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2026-05-22T10:16:33.000Z - 25 days ago

Summit Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Bernstein starts Summit with an Underperform, says ‘not on solid footing’

2026-05-21T21:26:44.000Z - 25 days ago

Bernstein starts Summit with an Underperform, says ‘not on solid footing’

Summit Therapeutics initiated with an Underperform at Bernstein

2026-05-21T20:28:05.000Z - 25 days ago

Summit Therapeutics initiated with an Underperform at Bernstein

3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22

2026-05-18T20:12:08.000Z - 4 weeks ago

3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22

BSX ZETA

Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

May 4, 2026, 9:23 AM EDT - 6 weeks ago

Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

Apr 30, 2026, 4:32 PM EDT - 6 weeks ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

Summit Therapeutics Earnings release: Q1 2026

Apr 30, 2026, 4:00 PM EDT - 6 weeks ago

Summit Therapeutics Earnings release: Q1 2026

Summit Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 4:00 PM EDT - 6 weeks ago

Summit Therapeutics Quarterly report: Q1 2026

Summit Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Summit Therapeutics Proxy statement: Proxy filing

Summit Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Summit Therapeutics Proxy statement: Proxy filing

Summit Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Summit Therapeutics Proxy statement: Proxy filing

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

Mar 27, 2026, 8:15 AM EDT - 2 months ago

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

Summit Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 2:15 PM EDT - 3 months ago

Summit Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Summit Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 2:30 PM EST - 3 months ago

Summit Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Summit Therapeutics to Present at Upcoming Investor Conferences

Feb 26, 2026, 6:45 PM EST - 3 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Summit Therapeutics Earnings Call Transcript: Q4 2025

Summit Therapeutics Annual report: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Summit Therapeutics Annual report: Q4 2025

Summit Therapeutics Earnings release: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Summit Therapeutics Earnings release: Q4 2025

Summit Therapeutics Slides: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Summit Therapeutics Slides: Q4 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Feb 23, 2026, 4:05 PM EST - 4 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Feb 17, 2026, 5:05 PM EST - 4 months ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 30, 2026, 4:30 PM EST - 4 months ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Jan 29, 2026, 7:30 AM EST - 4 months ago

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Summit Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:45 PM EST - 5 months ago

Summit Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:45 PM EST - 5 months ago

Summit Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

Jan 12, 2026, 6:15 AM EST - 5 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

GSK

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Jan 12, 2026, 6:00 AM EST - 5 months ago

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:30 AM EST - 5 months ago

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 2:10 PM EST - 6 months ago

Summit Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Summit Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 10:30 AM EST - 7 months ago

Summit Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Summit Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 10:30 AM EST - 7 months ago

Summit Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Summit Therapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 3:30 PM EST - 7 months ago

Summit Therapeutics Transcript: UBS Global Healthcare Conference 2025

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Nov 7, 2025, 9:00 AM EST - 7 months ago

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Oct 31, 2025, 7:00 AM EDT - 8 months ago

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Summit Therapeutics Raises $500 Million in Private Placement

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Summit Therapeutics Raises $500 Million in Private Placement

Summit Therapeutics Earnings Call Transcript: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Summit Therapeutics Earnings Call Transcript: Q3 2025

Summit Therapeutics Earnings release: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Summit Therapeutics Earnings release: Q3 2025

Summit Therapeutics Quarterly report: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Summit Therapeutics Quarterly report: Q3 2025

Summit Therapeutics Slides: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Summit Therapeutics Slides: Q3 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Oct 20, 2025, 6:45 AM EDT - 8 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Oct 19, 2025, 10:30 AM EDT - 8 months ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Oct 17, 2025, 7:00 AM EDT - 8 months ago

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Oct 15, 2025, 7:00 AM EDT - 8 months ago

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 24, 2025, 7:00 AM EDT - 9 months ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 17, 2025, 10:54 PM EDT - 9 months ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 16, 2025, 4:31 PM EDT - 9 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 9 months ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Summit Therapeutics Transcript: Study Update

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Transcript: Study Update

Summit Therapeutics Press release: Study Update

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Press release: Study Update

Summit Therapeutics Slides: Study Update

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Slides: Study Update

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 6:08 AM EDT - 10 months ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 7, 2025, 3:30 AM EDT - 10 months ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Sep 3, 2025, 7:00 AM EDT - 10 months ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Aug 11, 2025, 5:03 PM EDT - 11 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Summit Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Summit Therapeutics Earnings release: Q2 2025

Summit Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Summit Therapeutics Quarterly report: Q2 2025

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Summit Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 9, 2025, 1:20 PM EDT - 1 year ago

Summit Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Is SMMT Stock A Buy After Its Recent Plunge?

Jun 2, 2025, 9:10 AM EDT - 1 year ago

Is SMMT Stock A Buy After Its Recent Plunge?

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:27 AM EDT - 1 year ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 30, 2025, 6:00 AM EDT - 1 year ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 1 year ago

Final Trade: NVS, XLU and SMMT

NVS XLU

Summit Therapeutics Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Earnings Call Transcript: Q1 2025

Summit Therapeutics Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Quarterly report: Q1 2025

Summit Therapeutics Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Earnings release: Q1 2025

Summit Therapeutics Slides: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Slides: Q1 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

May 1, 2025, 4:09 PM EDT - 1 year ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Summit Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Summit Therapeutics Proxy statement: Proxy Filing

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Apr 25, 2025, 2:50 PM EDT - 1 year ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Apr 23, 2025, 6:15 AM EDT - 1 year ago

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

ItsMuffinMan
ItsMuffinMan Jun. 16 at 4:31 PM
$SMMT
0 · Reply
Bazziggr
Bazziggr Jun. 16 at 4:07 PM
$SMMT JUNK
0 · Reply
Dragonland
Dragonland Jun. 16 at 2:08 PM
$SMMT really expected more momentum from the buys last week. Market still very down on Summit for some strange reason.
1 · Reply
DakHart
DakHart Jun. 16 at 11:55 AM
$SMMT
0 · Reply
SmokeWagon
SmokeWagon Jun. 16 at 10:30 AM
$SMMT !!! The Tide has turned.
0 · Reply
paweltrader
paweltrader Jun. 16 at 3:36 AM
$SMMT Officer Zanganeh Mahkam bought 3.8M shares for $49.99M. Real-time insider alerts, no delay. watch4insider.com
0 · Reply
DakHart
DakHart Jun. 16 at 1:09 AM
$SMMT was really hopeful this morning for a push back to 15. I do think 15 is obtainable this week tho!
0 · Reply
Reneejordan001
Reneejordan001 Jun. 15 at 7:36 PM
$SMMT Just started enrollment for Triple negative breast cancer 👇👌
1 · Reply
DakHart
DakHart Jun. 15 at 7:26 PM
$SMMT might have to wait for some good trial data come August timeframe. I fear the dilution fears are too strong for the insider signals to matter for large growth.
1 · Reply
Boom1166
Boom1166 Jun. 15 at 5:43 PM
$SMMT
0 · Reply
SmokeWagon
SmokeWagon Jun. 15 at 4:59 PM
$SMMT !!!
0 · Reply
HedgeFollow
HedgeFollow Jun. 15 at 3:14 PM
. 🔍 𝗡𝗘𝗪 𝗟𝗔𝗥𝗚𝗘 𝗕𝗨𝗬𝗦 🔎 Among the 𝗟𝗮𝗿𝗴𝗲𝘀𝘁 𝗜𝗻𝘀𝗶𝗱𝗲𝗿 𝗕𝘂𝘆𝘀 in the past week: $BKKT - over $2M by Mike Alfred, @mikealfred, a Board member (his 2nd large buy within just 1 month!!) $DBGI - $1M by CEO himself $SMMT - a total of $100M by 2 top insiders Source: hedgefollow.com/largest-insider-buys.php
0 · Reply
letstalk8
letstalk8 Jun. 15 at 2:11 PM
$SMMT Love this
3 · Reply
officialshawn
officialshawn Jun. 15 at 1:48 PM
$SMMT Bob posted a video on his instagram about his recent $50,000,000 purchase. He is getting close to a billion invested and I think he will will probably be there soon. $PLSE $ISRG $ABBV
1 · Reply
SmokeWagon
SmokeWagon Jun. 15 at 12:49 PM
$SMMT !!!
0 · Reply
Megabyte48
Megabyte48 Jun. 15 at 12:05 PM
$SMMT Buckle up
0 · Reply
TruthBroker2
TruthBroker2 Jun. 15 at 11:52 AM
$SMMT.
0 · Reply
SmokeWagon
SmokeWagon Jun. 14 at 3:29 PM
$SMMT !!!
0 · Reply
georgenabi
georgenabi Jun. 14 at 3:04 PM
$SMMT Monday we runnin!
0 · Reply
TruthBroker2
TruthBroker2 Jun. 14 at 2:46 PM
$SMMT Team Summit
1 · Reply
THEvigilante
THEvigilante Jun. 14 at 2:19 PM
$SMMT What did i tell you...sorry but it was clear as day to those who have seen this played over & over on high-retail tickers
2 · Reply
TopTierNewswire
TopTierNewswire Jun. 14 at 3:44 AM
$SMMT - Large Insider Buys at $13.12 reported on 6/12. Stock pushed on higher. On watch!
0 · Reply